Compare Halozyme Therapeutics Inc. Common Stock (HALO) vs Micron Technology, Inc. (MU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Halozyme Therapeutics Inc. Common Stock vs Micron Technology, Inc. — how do they compare? Halozyme Therapeutics Inc. Common Stock trades at $112.3 (market cap $12.58B), while Micron Technology, Inc. trades at $1,028.32 (market cap $1.17T). The key difference: Micron Technology, Inc. is far larger — about 93× Halozyme Therapeutics Inc. Common Stock's market cap, and Micron Technology, Inc. pays a 0.06% dividend while Halozyme Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Halozyme Therapeutics Inc. Common Stock for 0 Days and Micron Technology, Inc. for 48 Days on average.
| HALO | MU | |
|---|---|---|
Market Cap | $12.58B | $1.17T |
Volume | 2,179,278 | 29,425,906 |
Sector | Health | Technology |
52-Week High | $115.22 | $1.21K |
52-Week Low | $61.63 | $181.60 |
Typical Hold Time | 0 Days | 48 Days |
Enterprise Value | $14.49B | $1.13T |
Dividend Yield | — | 0.06% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Micron Technology (MU) trades at $1,026.85, down 5.62% over 24 hours, despite strong fundamental performance. The stock shows bullish technical signals with support at $1,020 and resistance at $1,064. Recent earnings have consistently beaten expectations, with Q2 2026 EPS of $33.42 surpassing the $31.77 estimate. Revenue surged to $37.38 billion in 2025 with net income of $8.54 billion, while analyst consensus remains strongly bullish with 82.85% buy ratings and a $1,590 price target.
Outlook remains positive driven by AI memory demand and strategic customer agreements covering 35% of revenue through 2030. Key risks include cyclical memory pricing and potential growth deceleration. The valuation at P/E 13.94 appears reasonable given robust profitability margins and projected 2026 revenue of $133.2 billion. Institutional sentiment supports further upside if execution continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Halozyme Therapeutics Inc. Common Stock
Halozyme Therapeutics develops drug-delivery technologies for biopharmaceutical companies. Its ENHANZE technology uses the rHuPH20 enzyme to support subcutaneous delivery of co-administered medicines.
Read more on HALO →About Micron Technology, Inc.
Micron historically focused on designing and manufacturing DRAM for PCs. The firm then expanded into the NAND flash memory market. It increased its DRAM scale with the purchase of Elpida (completed in mid-2013) and Inotera (completed in December 2016). The firm's DRAM and NAND products tailored to PCs, data centers, smartphones, game consoles, automotives, and other computing devices.
Read more on MU →
